NCT02356133 is a clinical trial in Near-Infrared Spectroscopy in Endovascular Neurosurgery, sponsored by China International Neuroscience Institution.

Who is sponsoring NCT02356133?

NCT02356133 is sponsored by China International Neuroscience Institution.

What condition does NCT02356133 study?

NCT02356133 studies Near-Infrared Spectroscopy in Endovascular Neurosurgery.

Is NCT02356133 still recruiting?

NCT02356133 is currently completed. Last updated 7 August 2018.

Last reviewed 2018-08-07 · How we verify

NCT02356133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Relationship Among rSO2, MAP, et al by Near-Infrared Spectroscopy in Endovascular Neurosurgery

Completed Last updated 7 August 2018

What this trial tests

trial in Near-Infrared Spectroscopy in Endovascular Neurosurgery in 43 participants. Completed in 1 May 2017.

Timeline

1 May 2015

Primary endpoint
1 January 2017

1 May 2017

Quick facts

Lead sponsor	China International Neuroscience Institution
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	1 May 2015
Primary completion	1 January 2017
Estimated completion	1 May 2017

Conditions studied

Near-Infrared Spectroscopy in Endovascular Neurosurgery — all drugs for Near-Infrared Spectroscopy in Endovascular Neurosurgery →

Sponsor

China International Neuroscience Institution — full company profile →

Who can join

Adults 18 to 80, any sex, with Near-Infrared Spectroscopy in Endovascular Neurosurgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

record,describe and discuss the relationship among rSO2, MAP,CAM value, vital organ disfunction and the outcome of patients after operation by Near-Infrared Spectroscopy in Endovascular Neurosurgery

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Regional cerebral oxygen saturation and postoperative delirium in endovascular surgery: a prospective cohort study.
Wang X, Feng K, Liu H, Liu Y, et al · · 2019 · cited 30× · PMID 31412906 · DOI 10.1186/s13063-019-3586-y

Verify or expand the search:

Other China International Neuroscience Institution trials

Trials by the same sponsor.

NCT06946277 — Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG · Phase 4 · not yet recruiting
NCT06671327 — Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain · Phase 4 · not yet recruiting
NCT06662656 — ED50 of Sufentanil for Intraoperative Analgesia · not yet recruiting
NCT05500703 — Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia · Phase 4 · completed
NCT04432675 — Effects of Crystal Solution and Colloid Solution on Mother and Fetus · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02356133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China International Neuroscience Institution
Last refreshed: 7 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02356133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing